A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies
Jiaxi Wu,Nicolin Bloch,Aaron Y Chang,Ramandeep Bhavsar,Qingqing Wang,Alison Crawford,David J DiLillo,Kristin Vazzana,Katja Mohrs,Drew Dudgeon,Supriya Patel,Hassan Ahmed,Vidur Garg,Michael Amatulli,Olivia Q Antao,Yuetian Yan,Shunhai Wang,Willy Ramos,Pamela Krueger,Christina Adler,Min Ni,Yi Wei,Chunguang Guo,Lynn Macdonald,Tammy Huang,Erica Ullman,Aynur Hermann,George D Yancopoulos,Andrew J Murphy,Samuel Davis,William C Olson,John C Lin,Eric Smith,Tong Zhang
DOI: https://doi.org/10.1016/j.xcrm.2024.101747
2024-10-15
Abstract:The clinical use of interleukin-2 (IL-2) for cancer immunotherapy is limited by severe toxicity. Emerging IL-2 therapies with reduced IL-2 receptor alpha (IL-2Rα) binding aim to mitigate toxicity and regulatory T cell (Treg) expansion but have had limited clinical success. Here, we show that IL-2Rα engagement is critical for the anti-tumor activity of systemic IL-2 therapy. A "non-α" IL-2 mutein induces systemic expansion of CD8+ T cells and natural killer (NK) cells over Tregs but exhibits limited anti-tumor efficacy. We develop a programmed cell death protein 1 (PD-1)-targeted, receptor-masked IL-2 immunocytokine, PD1-IL2Ra-IL2, which attenuates systemic IL-2 activity while maintaining the capacity to engage IL-2Rα on PD-1+ T cells. Mice treated with PD1-IL2Ra-IL2 show no systemic toxicities observed with unmasked IL-2 treatment yet achieve robust tumor growth control. Furthermore, PD1-IL2Ra-IL2 can be effectively combined with other T cell-mediated immunotherapies to enhance anti-tumor responses. These findings highlight the therapeutic potential of PD1-IL2Ra-IL2 as a targeted, receptor-masked, and "α-maintained" IL-2 therapy for cancer.